Mechanism of Action and Persistence of Neuroprotection by Cell-Permeant Ca2+Chelators
Author(s) -
Michael Tymianski,
Igor Spigelman,
Liang Zhang,
Peter L. Carlen,
Charles H. Tator,
Milton P. Charlton,
M. Christopher Wallace
Publication year - 1994
Publication title -
journal of cerebral blood flow and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.167
H-Index - 193
eISSN - 1559-7016
pISSN - 0271-678X
DOI - 10.1038/jcbfm.1994.122
Subject(s) - bapta , excitatory postsynaptic potential , neuroprotection , chemistry , nmda receptor , pharmacology , biophysics , membrane potential , ischemia , electrophysiology , neurotransmission , in vivo , neuroscience , anesthesia , intracellular , medicine , biochemistry , biology , microbiology and biotechnology , receptor
Cell-permeant Ca 2+ chelators such as 1,2-bis-(2-aminophenoxy)ethane- N,N,N′,N′-tetraacetic acid acetoxymethyl ester (BAPTA-AM) have been reported to protect neurons in experimental focal cerebral ischemia. However, their in vivo actions are uncertain, and their protective efficacy is proven only in brief cerebral ischemia paradigms. Here we examine their mechanism of action in vitro and duration of efficacy in vivo. Electrophysiological studies were made in CA1 neurons in rat hippocampal slices. When superfused with BAPTA-AM (30–50 μ M), CA1 somatic field potential recordings showed attenuation of the population spike amplitude, and intracellular recordings showed reduced excitatory postsynaptic potentials, indicating inhibition of excitatory synaptic transmission. Also, Ca 2+ -dependent accommodation and post-spike-train hyperpolarizations were reduced, indicating Ca 2+ chelation hear the internal cell membrane surface. To determine whether Ca 2+ chelators reduce the size of cerebral infarction rather than simply delaying its evolution, we studied the effects of BAPTA-AM treatment on infarction size 24 h after permanent middle cerebral artery occlusion. Fischer rats ( n = 8 per group) were pretreated with saline, BAPTA-AM (20 mg/kg), or MK-801 (0.5 mg/kg). Infarction volumes in animals treated with BAPTA-AM were reduced by 50.5% compared with controls ( p = 0.018), whereas animals treated with MK-801 experienced a statistically insignificant infarct volume reduction (26%; p = 0.27). These data show a persistence of neuroprotection by the Ca 2+ chelator at 24 h and indicate that it may act by attenuating synaptic transmission and subplasma membrane Ca 2+ excess.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom